Premium
Omega‐3 and hemocompatibility‐related adverse events
Author(s) -
Imamura Teruhiko,
Nguyen Ann,
Rodgers Daniel,
Kim Gene,
Raikhelkar Jayant,
Kalantari Sara,
Narang Nikhil,
Juricek Colleen,
Ota Takeyoshi,
Jeevanandam Valluvan,
Sayer Gabriel,
Uriel Nir
Publication year - 2020
Publication title -
journal of cardiac surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.428
H-Index - 58
eISSN - 1540-8191
pISSN - 0886-0440
DOI - 10.1111/jocs.14384
Subject(s) - medicine , confidence interval , hazard ratio , adverse effect , observational study , omega , propensity score matching , cardiology , surgery , physics , quantum mechanics
Background Hemocompatibility‐related clinical adverse events (HRAEs) are major causes of readmission in patients with left ventricular assist devices (LVADs). Omega‐3 is an unsaturated fatty acid that possesses anti‐inflammatory and antiangiogenic properties. We aimed to investigate the impact of omega‐3 therapy on HRAEs during LVAD support. Methods Consecutive LVAD patients who were followed for 6 months were enrolled, and stratified by the use of omega‐3. Freedom from any HRAEs and net burden of HRAEs, which was calculated by using a hemocompatibility score (using 4 escalating tiers of hierarchal severity to derive a total score for events), were compared between those with and without omega‐3 therapy. Results Among 169 LVAD patients (57 years old and 124 males), 31 patients received 4 g/d of omega‐3 therapy and 138 patients were in the control group. During the 6‐month observational period, freedom from any HRAEs was 90% in the omega‐3 group compared with 70% in the control group with a hazard ratio of 0.35 (95% confidence interval 0.11–0.87 and P = .042). The average hemocompatibility score in the omega‐3 group was significantly lower compared with the control group (0.23 vs 0.91; P = .042), due to reduced Tier I scores (mild HRAE; P = .003) and Tier IIIB scores (severe HRAE; P < .001). The similar trends remained at propensity‐matched populations. Conclusions Omega‐3 therapy was associated with reduced HRAEs including both bleeding and thromboembolic events in LVAD patients.